Evaxion A/S · NASDAQ:EVAX

Evaxion A/S — Q3 2026 Earnings Presentation

22 slides from Evaxion A/S's earnings presentation, Nov 19, 2026

  1. Slide 1: Strategy & business update Q3 2026

    NOVEMBER 19, 2026 Strategy & business update Q3 2026 Helen Tayton-Martin, CEO Birgitte Rønø, CSO & COO Thomas Schmidt, CFO Mads Kronborg, VP Investor Relations and Communication

  2. Slide 2: Agenda

    1. Strategy update (Helen Tayton-Martin) 2. R&D and AI-Immunology™ update (Birgitte Rønø) Agenda 3. Q3 2026 financial results (Thomas Schmidt) 4. Concluding remarks (Helen Tayton-Martin) 5. Q&A © Evaxion A/S. All rights reserved. 2

  3. Slide 3: Forward-looking statement

    Forward-looking statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “m

  4. Slide 4: 1. Strategy update

    1. Strategy update © Evaxion A/S. All rights reserved. 4

  5. Slide 5: Evaxion – re-focusing the strategy in a new era for cancer vaccines and AI

    Evaxion – re-focusing the strategy in a new era for cancer vaccines and AI Evaxion has produced compelling clinical and translational data with its own personalized cancer vaccine EVX-01 Evaxion has a unique platform in AI- Evaxion can design off-the-shelf Immunology™ able to predict and design and

  6. Slide 6: Evaxion pipeline focus going forward

    Evaxion pipeline focus going forward ONCOLOGY P RO GRAM IN DICATIO N AP P RO ACH TARGE T DIS CO V E RY P RE CL IN ICAL P HAS E 1 P HAS E 2 EVX-01 Advanced melanoma Personalized (Liposomal/peptide) EVX-04 Acute myeloid Off-the-shelf (DNA) leukemia EVX-05 Glioblastoma Off-the-shelf (DNA) Multiple Pers

  7. Slide 7: Key achievements since last business update

    Key achievements since last business update AI-Immunology™ Business development R&D Financing platform • Multiple parallel • New data for EVX-01 • Winning the 2026 • Disciplined resource partnership discussions presented at ESMO and International Prix Galien allocation aligned with SITC Award for Be

  8. Slide 8: 2026 milestones

    2026 milestones H1 H2 H2 H2 H2 EVX-01 AI-Immunology™ EVX-01 EVX-B4 EVX-04 Personalized vaccine for Personalized vaccine for Vaccine for Group A Off-the-shelf vaccine for advanced melanoma advanced melanoma Streptococcus Acute Myeloid Leukemia Additional biomarker New application for Three-year phase

  9. Slide 9: 2. R&D and AI-Immunology™ update

    2. R&D and AI-Immunology™ update © Evaxion A/S. All rights reserved. 9

  10. Slide 10: AI-Immunology™ predicts neoantigens for personalized cancer treatment

    AI-Immunology™ predicts neoantigens for personalized cancer treatment AI-Immunology™ is part of a larger process Neoantigens are ideal cancer vaccine targets from patient tumor to personalized treatment • They arise from cancer-specific • Total turnaround time from patient biopsy to vaccine DNA muta

  11. Slide 11: EVX-01: 75% Objective and 25% Complete Response Rate

    EVX-01: 75% Objective and 25% Complete Response Rate Endpoints main phase (FU 2Y) Overall improvement in response from SD or PR 7/13 (54%) at Week 12 Improvement from SD to PR 4/6 (67%) Improvement from PR to CR 3/7 (43%) Objective Response Rate 12/16 (75%) Treatment emerging AEs (EVX-01-related) On

  12. Slide 12: EVX-01 demonstrates record-high target precision rate throughout the study duration

    EVX-01 demonstrates record-high target precision rate throughout the study duration EVX-01 induces vaccine-specific T-cells EVX-01 vaccine neoantigens induce potent and responses are sustained throughout specific T-cell responses three-year study period 89% 86% Immunogenic de novo neoAg vaccine neoA

  13. Slide 13: EVX-01 induces both CD4+ and CD8+ antigen-specific T-cell responses

    EVX-01 induces both CD4+ and CD8+ antigen-specific T-cell responses; very precise neoantigen prediction Patient CD4+ CD8+ Positive correlation between vaccine target AI-prediction ID response response scores and the magnitude of the immune response1 1 ✓ ✓ 2 ✓ ✓ 3 ✓ ✓ 4 ✓ ✓ 5 ✓ ✓ 6 ✓ ✓ 7 ✓ ✓ 8 ✓ 9 ✓

  14. Slide 14: Unique scalability across indications, patients and vaccine approaches

    Unique scalability across indications, patients and vaccine approaches COMPLEX PROGRAMS & PATIENT OMICS DATA AI-IMMUNOLOGY™ VACCINE APPROACH INDICATIONS Melanoma | EVX-01 Head and neck Personalized Lung Genomic Patient-tailored Ovarian DNA variants vaccines targeting private (neo)antigens Bladder AI

  15. Slide 15: Strategic advantages from broad discovery scope and very high target precision

    Strategic advantages from broad discovery scope and very high target precision AI-IMMUNOLOGY™ DIFFERENTIATION STRATEGIC PRODUCT OPPORTUNITY 01 02 03 04 Multiple antigen High target Broader indication Higher likelihood of sources à broader precision reach clinical success discovery scope • Neoantigen

  16. Slide 16: AI-Immunology™'s unique capabilities in finding ERV-targets allows novel treatment concept for AML

    AI-Immunology™’s unique capabilities in finding ERV- targets allows novel treatment concept for AML EVX-04 DEVELOPMENT STAGE EVX-04 PATIENT AI-IMMUNOLOGY™ LEAD CANDIDATE LEAD & TARGET CTA*-ENABLING CLINICAL SEQUENCING ANTIGEN MINING SELECTION VALIDATION ACTIVITIES DEVELOPMENT ERV tumor antigens From

  17. Slide 17: 3. Q3 2026 Financial results

    3. Q3 2026 Financial results © Evaxion A/S. All rights reserved. 17

  18. Slide 18: Financials – Q3 2026 highlights

    Financials – Q3 2026 highlights • Cash runway extended towards end of 2027 through utilization of our At-the-Market (ATM) program and fully supporting the strategy update • We have and will continue our disciplined resource allocation fully aligned with the updated strategy and prioritized value dri

  19. Slide 19: Financials – Q3 2026 Profit & Loss

    Financials – Q3 2026 Profit & Loss • No revenue recognized in Q3 2026, compared to out-licensing Three months ended September 30, of EVX-B3 to MSD last year 2026 2025 Revenue • Research and Development expenses reduced mainly due to - 7,492 fewer headcount Research and development (2,312) (3,092) Ge

  20. Slide 20: Financials – Q3 2026 Balance Sheet

    Financials – Q3 2026 Balance Sheet • In August 2026, we utilized our ATM facility with gross proceeds September 30, 2026 December 31, 2025 of $2.2 million Cash and cash equivalents 13,274 23,234 • Cash and cash equivalents balance of $13.3 million, extending Total assets 18,665 28,408 our current ca

  21. Slide 21: 4. Concluding remarks

    4. Concluding remarks © Evaxion A/S. All rights reserved. 21

  22. Slide 22: Concluding remarks

    Concluding remarks Refocused strategy to maximize value of assets and capabilities in immuno-oncology Continued validation of the unique capabilities and scalability of AI-Immunology™ as well as individual programs Business development remains a key priority, multiple parallel discussions ongoing Ca

Evaxion — Q3 2026 Earnings Presentation on 6ix